Matt Sagan, Founder, Managing Partner, and CEO of MoD Partners, as well as Co-Founder, Chief Growth & Strategy Officer, and Board Member at VAXiCAN, shared a post on X:
“Is It Time To Rethink How We Measure HER2?
Trastuzumab deruxtecan (T-DXd) has transformed treatment for metastatic breast cancer, but responses still vary widely. In a recent study, patients with higher quantitative HER2 levels experienced significantly longer treatment benefit, with time to next treatment reaching ~10.4 months in HER2-positive disease vs ~7.6 months in HER2-low tumors. These findings suggest we may need to move beyond HER2 status → toward quantitative HER2 biology.
I think there is no time to rethink how we measure HER2 in Breast Cancers (and many other as well) T-DXd ADC has already transformed treatment for MBC and may transform HER2 treatment in general, specially when it comes to HER2 low and HER2 ultralow. Cancer Vaccines are next potential wave of cancer treatment innovation and they will also be more efficient with more sensitive numerical based diagnostics.
Traditional IHC or FISH techniques are no longer relevant, are not sensitive enough and what is most important are not objective are still in vitro (requiring tissue biopsy). This is why we need as soon as possible novel HER2 diagnostic tools, including NGS or in vivo techniques, like in PROBE from SDS Optic.”
Quantitative HER2 Profiling May Refine How We Use Trastuzumab Deruxtecan In Metastatic Breast Cancer
